{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-153075","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.464640+00:00","generated_at":"2026-06-01T06:50:31.177033+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024","bullets":["Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.","Paltusotine: PATHFNDR-2 met primary endpoint – 56% on drug vs 5% placebo achieved IGF-1 ≤1.0xULN (p<0.0001).","PATHFNDR-1 PRO analysis: paltusotine reduced breakthrough symptom exacerbations vs prior injectable SRLs.","Long-term ACROBAT Advance: stable IGF-1, symptom control, and safety at up to 42 months.","Crinetics expects to complete NDA submission for paltusotine in 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-153075","json":"https://secwatch.observer/filing/0001193125-24-153075.json","markdown":"https://secwatch.observer/filing/0001193125-24-153075.md","text":"https://secwatch.observer/filing/0001193125-24-153075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/0001193125-24-153075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524153075/d823838d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:50:31.177033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}